ICON plc reports developments for a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology companies. Its news commonly covers operating and financial results, clinical trial management activity, net business wins, revenue guidance, and service areas such as patient recruitment, data analytics, laboratory services and regulatory consulting.
Company updates also address partnerships that connect clinical trial technology with research-site systems, expansion of the Accellacare Site Network in therapeutic areas including oncology, and governance or accounting-control matters tied to revenue recognition and financial reporting.
ICON plc (NASDAQ: ICLR) reported third quarter 2022 results showcasing strong financial performance. Net business wins reached $2,351 million, with a book-to-bill ratio of 1.21. Revenue for Q3 was $1,942.4 million, up 3.9% year-on-year. Year-to-date revenue hit $5,779.4 million, reflecting a 60.6% increase. Adjusted EBITDA stood at $379.6 million, representing 19.5% of revenue. Adjusted net income was $247.2 million, leading to $3.00/b per diluted share. The company reaffirmed its full-year guidance, anticipating revenue between .
ICON plc (NASDAQ: ICLR) has been selected by the US Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical trial for the AV7909 anthrax vaccine. Funded by BARDA, this trial aims to evaluate the immune response of healthy adults to the next-generation vaccine, with activities including project management and clinical operations. ICON has significant experience in vaccine studies, participating in over 160 trials in the past five years. The trial will start in early 2023, addressing the potential threat of anthrax exposure.
ICON plc (NASDAQ: ICLR) will release its Q3 2022 financial results on November 2, 2022, post market close. A conference call will follow on November 3, 2022, at 8:00 AM ET to discuss the results. As of June 30, 2022, ICON employed approximately 40,500 staff across 119 locations in 53 countries. The firm emphasizes its role in advancing clinical research and patient care, but noted that forward-looking statements are subject to risks that could affect actual results. Further updates will be provided on the Investor Relations section of the ICON website.
Summary not available.
ICON plc (NASDAQ: ICLR), a global leader in healthcare intelligence and clinical research, announced that CFO Brendan Brennan will present at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 10:25 AM EDT. The presentation will be accessible via a live webcast, with any updates available on their investor website under the 'Events' section. ICON, headquartered in Dublin, Ireland, employs approximately 40,500 individuals across 119 locations in 53 countries as of June 30, 2022.
ICON plc (NASDAQ: ICLR) announced that all resolutions during its Annual General Meeting on July 26, 2022, were approved by shareholders. Key resolutions included the re-election of directors and the authorization to allot shares. Major retirements from the Board were noted, including Professor William Hall and Ms. Mary Pendergast, who have served since 2013 and 2014, respectively. The meeting reflects ICON's commitment to governance and shareholder engagement, with approximately 68.8 million votes cast on various resolutions, affirming shareholder confidence.
ICON plc (NASDAQ: ICLR) reported strong Q2 2022 results with net business wins of $2,323 million and a book-to-bill ratio of 1.20. Revenue reached $1,935.2 million, up 122.1% year-over-year. Adjusted EBITDA stood at $354.3 million, 18.3% of revenue, reflecting a yearly increase of 120.2%. Adjusted net income was $235.8 million, with earnings per share of $2.86. The company revised its full year 2022 revenue guidance to $7,690 - $7,810 million, anticipating a 40.3% to 42.5% increase year-over-year.
ICON, a leading healthcare intelligence and clinical research organization (NASDAQ: ICLR), will release its financial results for Q2 2022 on July 27, 2022, after market close. A conference call to discuss these results is scheduled for July 28, 2022, at 8:00am ET. This announcement underscores ICON's dedication to transparency and investor communication. As of March 31, 2022, ICON employed approximately 39,300 individuals across 138 locations globally, emphasizing its expansive operational capacity.
ICON plc (NASDAQ: ICLR) announced that CFO Brendan Brennan will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 AM ET. Additionally, CEO Steve Cutler is set to present at the Jefferies Healthcare Conference on June 9, 2022, at 2:00 PM ET, with live webcasts available. As of March 31, 2022, ICON employed approximately 39,300 employees across 138 locations in 53 countries, providing outsourced services in clinical research to various sectors. For updates, visit the Investor section on ICON's website.
ICON plc (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, announced that CFO Brendan Brennan will present at the BofA Securities 2022 Healthcare Conference on May 10, 2022, at 5:20 PM PT. The presentation details will be available on their Investor Relations website, under the 'Events' section. ICON, headquartered in Dublin, Ireland, employs approximately 39,300 staff across 138 locations in 53 countries, providing services to various health organizations.